LightNews LightNews
k9luna.bsky.social
@k9luna.bsky.social
53 followers 200 following 59 posts
Posts Replies Media Videos
k9luna.bsky.social
In my experience, the more a story is embellished after its initial telling, the more it is a lie.
December 7, 2025 at 4:06 AM
k9luna.bsky.social
She will be remembered as another delusional member of the trump outlaw gang
July 13, 2025 at 3:02 AM
k9luna.bsky.social
Need to give more attention to MSM selling out and actual journalism being done by independent platforms.
July 6, 2025 at 4:21 PM
k9luna.bsky.social
The pets are at risk.
June 6, 2025 at 3:06 PM
k9luna.bsky.social
No, it’s not incredible. It’s because only poor people commit fraud according to Mike Johnson.
June 2, 2025 at 6:28 PM
k9luna.bsky.social
They never live long enough.We lost a beloved aussie to lymphoma at age 3 1/2; he was gone in a few weeks and it was agonizing for all. There is no sense to be made of it; they are loving and loved, and then gone. Condolences, we have had the experience more times than I can count. But did it again.
May 28, 2025 at 3:24 AM
k9luna.bsky.social
In the People’s House, fps.
May 22, 2025 at 7:21 PM
Reposted
sailorrooscout.bsky.social
The study has been published in Alzheimer’s & Dementia. YES, it is PEER-REVIEWED.
• alz-journals.onlinelibrary.wiley.com/doi/10.1002/...
• hscnews.unm.edu/news/unm-res...
SUMMARY Researchers have developed a tau-targeting vaccine that could help prevent the progression of Alzheimer's disease by generating a strong immune response against abnormal tau proteins. The vaccine showed effectiveness in mice and non-human primates, prompting researchers to pursue human clinical trials. It targets a specific region of the tau protein, pT181, linked to Alzheimer's-related brain damage and cognitive decline. If successful in humans, this approach could complement or even surpass current therapies that only modestly impact disease progression by targeting amyloid beta. KEY FACTS •Tau-Targeting Vaccine: Generates antibodies against pT181, a hallmark of Alzheimer's pathology. • Strong Immune Response: Proven effective in mice and macaques, with long-lasting immunity. •The vaccine improved memory, reduced brain atrophy, and caused NO major side effects. •Clinical Trials Ahead: Researchers are preparing for Phase I human trials pending funding. ABSTRACT INTRODUCTION Pathological accumulation of tau (pTau) contributes to various tauopathies, including Alzheimer's disease (AD), and correlates with cognitive decline. A rapid surge in tau-targeted approaches via anti-sense oligonucleotides, active/passive immunotherapies suggests that targeting p-Tau is a viable strategy against tauopathies. METHOD We describe a multi-species validation of our previously described Qß virus-like particle (VLP)-based vaccine technology targeting phosphorylated tau on threonine 181 (pT181-Qß). RESULTS Two vaccine doses of pT181-Qß, without any adjuvants, elicited robust antibody responses in two different mouse models of tauopathy (PS19 and hTau) and rhesus macaques. In mouse models, vaccination reduced AT180+ hyperphosphorylated, Sarkosyl insoluble, Gallyas silver positive tau, inflammasomes/ neuroinflammation, and improved recognition memory and motor function without inducing adverse T-cell activation. Anti-pT181 antibodies are reactive to pTau in human AD brains, engage pT181+ tau in human brain lysates, and are central nervous system bioavailable. DISCUSSION Our results suggest the translational utility of pT181-QB against tauopathies. Highlights • Icosahedral display of phosphorylated tau at threonine 181 (pT181) Qß virus-like particle surface ("pT181-Qß" vaccine) induces a robust immune response in mice and in non-human primates (NHPs) • pT181-Qß vaccination reduces pathological tau (pTau) and brain atrophy, and improves memory and motor function in PS19 and hTau mice. • pT181-Qß vaccination-induced immunoglobulin Gs (IgGs) are safe, Th2 skewed (anti-inflammatory), specific to pTau in human AD brain, and efficiently engage pT181 in NHPs and human brain lysate. • pT181+ tau in human plasma correlates with the neurofilament light in subjects with mild cognitive impairment (MCI)-suggesting the presence of pT181-Qß vaccine target in the early disease state. RESEARCH IN CONTEXT Systematic review: A literature review of PubMed and other literature sources suggests that the pathological modifications in tau protein strongly correlate with the cognitive decline in Alzheimer's disease (AD) and related dementias. As such, many pre-clinical and clinical trials have been targeting pathological tau to determine if such an approach benefits patients. Emerging clinical trials using monoclonal antibodies (mAbs) against different regions of tau show positive results in secondary outcomes of cognitive stabilization. Even if the mAb is approved for tau, repeated infusions of mAbs may have compliance issues in elderly patients and short-lived antibody responses upon active immunizations. The relevant citations and clinical trials are included where appropriate. Interpretation: Our study suggests that display of phosphorylated tau (on T181) peptide on the virus-like particles (VLPs) from Qß bacteriophage induced a robust immune response, reduced tau pathology, prevented brain atrophy, and improved memory, and that the immunoglobulin Gs (IgGs) from immunized sera engaged the target in vaccinated non-human primates (rhesus macaques) and human AD brains. Future directions: Targeting pT181-positive tau with pT181-Qß vaccination may in Phase 0/1 clinical trials validate the safety, immunogenicity, and therapeutic efficacy of pT181-Qß vaccination in patients with AD and related tauopathies.
May 5, 2025 at 4:02 PM
k9luna.bsky.social
I will be asking my reps this every day. They can’t carry us all out of the country.
May 6, 2025 at 1:26 PM
k9luna.bsky.social
Because trump, musk and the oligarchs get ALL the Raggedies.
April 30, 2025 at 6:46 PM